trial

Biomarkers in Clozapine-responding Schizophrenia

NCTId NCT05316883
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 200 (estimated)
Sponsored by Jimmi Nielsen
Primary completion 2029-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
200 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-02-28
Primary completion
2029-12-31
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Clozapine

Sponsors

Jimmi NielsenLead Sponsor

Investigators

1
Jimmi Nielsen, PhDPrincipal Investigator

Sites

1 total
Glostrup Municipality, Denmark

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE4
Primary Completion Date
2029-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Clozapine
drug
lead_sponsor
Jimmi Nielsen
company
indication
Schizophrenia
indication
Psychosis
indication
Schizophrenia
indication
investigator
Jimmi Nielsen, PhD
person